Telix Pharmaceuticals Limited (TLPPF)
TLPPF Stock Price Chart
Explore Telix Pharmaceuticals Limited interactive price chart. Choose custom timeframes to analyze TLPPF price movements and trends.
TLPPF Company Profile
Discover essential business fundamentals and corporate details for Telix Pharmaceuticals Limited (TLPPF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jul 2019
Employees
415.00
Website
https://telixpharma.comCEO
Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, MBA
Description
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLPPF Financial Timeline
Browse a chronological timeline of Telix Pharmaceuticals Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Feb 2026
Earnings released on 20 Aug 2025
EPS came in at -$0.01 falling short of the estimated $0.12 by -105.82%, while revenue for the quarter reached $399.18M , beating expectations by +20.97%.
Earnings released on 22 May 2025
Earnings released on 20 Feb 2025
EPS came in at $0.11 surpassing the estimated $0.09 by +20.37%, while revenue for the quarter reached $259.35M , beating expectations by +92.29%.
Earnings released on 22 Aug 2024
EPS came in at $0.02 falling short of the estimated $0.09 by -75.36%, while revenue for the quarter reached $125.99M , missing expectations by -67.76%.
Earnings released on 17 Apr 2024
EPS came in at $0.02 , while revenue for the quarter reached $74.05M , missing expectations by -35.11%.
Earnings released on 22 Feb 2024
EPS came in at $0.04 falling short of the estimated $0.05 by -18.28%, while revenue for the quarter reached $191.79M , beating expectations by +0.55%.
Earnings released on 9 Jan 2024
Earnings released on 23 Aug 2023
EPS came in at -$0.03 falling short of the estimated $0.04 by -181.01%, while revenue for the quarter reached $147.08M , beating expectations by +0.14%.
Earnings released on 30 Jun 2023
EPS came in at -$0.03 , while revenue for the quarter reached $146.66M .
Earnings released on 27 Feb 2023
EPS came in at -$0.02 surpassing the estimated -$0.05 by +67.15%, while revenue for the quarter reached $91.14M , beating expectations by +3.68%.
Earnings released on 31 Dec 2022
EPS came in at -$0.07 , while revenue for the quarter reached $92.98M .
Earnings released on 17 Aug 2022
EPS came in at -$0.16 falling short of the estimated -$0.08 by -95.09%, while revenue for the quarter reached $16.59M , missing expectations by -17.87%.
Earnings released on 30 Jun 2022
EPS came in at -$0.16 , while revenue for the quarter reached $16.53M .
Earnings released on 23 Feb 2022
EPS came in at -$0.12 falling short of the estimated -$0.06 by -119.50%, while revenue for the quarter reached $2.03M , missing expectations by -17.65%.
Earnings released on 31 Dec 2021
EPS came in at -$0.12 , while revenue for the quarter reached $3.40M .
Earnings released on 18 Aug 2021
EPS came in at -$0.09 falling short of the estimated -$0.09 by -0.52%, while revenue for the quarter reached $2.18M , beating expectations by +26.52%.
Earnings released on 30 Jun 2021
EPS came in at -$0.09 , while revenue for the quarter reached $2.18M .
Earnings released on 25 Feb 2021
EPS came in at -$0.07 falling short of the estimated $0.07 by -202.12%, while revenue for the quarter reached $2.78M , beating expectations by +89.47%.
Earnings released on 31 Dec 2020
EPS came in at -$0.08 , while revenue for the quarter reached $2.77M .
TLPPF Stock Performance
Access detailed TLPPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.